Liu Y - Search Results

1

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.

Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, Sun T, Teng Y, Wu X, Ouyang Q, Yan X, Cheng J, Liu Q, Feng J, Wang X, Yin Y, Shi Y, Pan Y, Wang Y, Xie W, Yan M, Liu Y, Yan P, Wu F, Zhu X, Zou J; DAWNA-1 Study Consortium. Xu B, et al. Among authors: liu y, liu q. Nat Med. 2021 Nov;27(11):1904-1909. doi: 10.1038/s41591-021-01562-9. Epub 2021 Nov 4. Nat Med. 2021. PMID: 34737452 Clinical Trial.

2

Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.

Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y, Li H, Yu S, Feng J, Wang S, Hu X, Zou J, Zhu X, Xu B. Ma F, et al. Among authors: liu y. J Clin Oncol. 2019 Oct 10;37(29):2610-2619. doi: 10.1200/JCO.19.00108. Epub 2019 Aug 20. J Clin Oncol. 2019. PMID: 31430226 Clinical Trial.

3

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.

Li J, Yu K, Pang D, Wang C, Jiang J, Yang S, Liu Y, Fu P, Sheng Y, Zhang G, Cao Y, He Q, Cui S, Wang X, Ren G, Li X, Yu S, Liu P, Qu X, Tang J, Wang O, Fan Z, Jiang G, Zhang J, Wang J, Zhang H, Wang S, Zhang J, Jin F, Rao N, Ma B, He P, Xu B, Zhuang Z, Wang J, Sun Q, Guo X, Mo M, Shao Z; CBCSG010 Study Group. Li J, et al. Among authors: liu y, liu p. J Clin Oncol. 2020 Jun 1;38(16):1774-1784. doi: 10.1200/JCO.19.02474. Epub 2020 Apr 10. J Clin Oncol. 2020. PMID: 32275467 Free PMC article. Clinical Trial.

4

Prognostic significance of preoperative albumin to fibrinogen ratio associated nomograms in patients with breast invasive ductal carcinoma.

Zheng L, Zhao Y, Liu F, Liu P, Li W, Yang Y, Zhang H, Liu Y. Zheng L, et al. Among authors: liu y, liu p, liu f. Medicine (Baltimore). 2020 Jun 26;99(26):e20681. doi: 10.1097/MD.0000000000020681. Medicine (Baltimore). 2020. PMID: 32590741 Free PMC article.

5

Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020.

Li J, Wang H, Geng C, Liu Z, Lin Y, Nie J, Sun G, Ouyang Q, Wang X, Li X, Liu Y, Chen Q, Fu P, Yao F, Chen J, Chen Y, Zhao H, Yin Y, Zhang J, Chen J, Kong X, Cheng J, Zhang H, Peng S, Wang G, Jin F, Liu Y, Wu G, Sun S, Jiang Z. Li J, et al. Among authors: liu z, liu y. EClinicalMedicine. 2020 Sep 24;26:100503. doi: 10.1016/j.eclinm.2020.100503. eCollection 2020 Sep. EClinicalMedicine. 2020. PMID: 32989430 Free PMC article.

6

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2- patients with metastatic breast cancer.

Li J, Zhang X, Yang C, Lv Y, Yang H, Kong X, Han M, Wang Z, Ma J, Han J, Liu Y. Li J, et al. Among authors: liu y. Medicine (Baltimore). 2021 Nov 5;100(44):e27710. doi: 10.1097/MD.0000000000027710. Medicine (Baltimore). 2021. PMID: 34871262 Free PMC article.

7

Full Compliance of Adjuvant Endocrine Therapy Is Associated with Higher Disease-Free Survival in Hormone Receptor-Positive and HER2-Negative Chinese Breast Cancer Patients with First Tumor Recurrence.

Li Z, Liu Y, Li Y, Shang Y, Du K, Ji X, Han H, Zhang J. Li Z, et al. Among authors: liu y. Asian Pac J Cancer Prev. 2022 Oct 1;23(10):3413-3420. doi: 10.31557/APJCP.2022.23.10.3413. Asian Pac J Cancer Prev. 2022. PMID: 36308366 Free PMC article.

8

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.

Wu J, Jiang Z, Liu Z, Yang B, Yang H, Tang J, Wang K, Liu Y, Wang H, Fu P, Zhang S, Liu Q, Wang S, Huang J, Wang C, Wang S, Wang Y, Zhen L, Zhu X, Wu F, Lin X, Zou J. Wu J, et al. Among authors: liu z, liu y, liu q. BMC Med. 2022 Dec 27;20(1):498. doi: 10.1186/s12916-022-02708-3. BMC Med. 2022. PMID: 36575513 Free PMC article. Clinical Trial.

9

Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China.

Xu B, Li H, Jiang Z, Gu L, Tang J, Xie H, Pan Y, Liu Y, Cui S, Wang X, Cai L, Zhang Y, Zhao H, Shao Z. Xu B, et al. Among authors: liu y. Chin J Cancer Res. 2022 Dec 30;34(6):592-600. doi: 10.21147/j.issn.1000-9604.2022.06.07. Chin J Cancer Res. 2022. PMID: 36714346 Free PMC article.

10

Trends in Disparities and Transitions of Treatment in Patients With Early Breast Cancer in China and the US, 2011 to 2021.

Li J, Zhou J, Wang H, Liu Z, Fan Z, Liu Y, Geng C, Xiao Y, Jiang Z; Chinese Society of Clinical Oncology Breast Cancer Committee Database Collaborative Group. Li J, et al. Among authors: liu z, liu y. JAMA Netw Open. 2023 Jun 1;6(6):e2321388. doi: 10.1001/jamanetworkopen.2023.21388. JAMA Netw Open. 2023. PMID: 37389867 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

190,921 results

Search Page